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host lymphocytes and consistent with our recent observations in
short-term cultures (Luznik, L. et al: Blood; in press), interesting- 
ly, M~l-specific allogeneic and host CD8 + T cells, expanded from 
the mixed chimeras had a higher affinity than the T cells derived 
from the vaccinated nontransplanted mice. In conclusion, mixed 
chimerism provides an optimal platform for immunotherapy of 
solid minors not only because of allogeneic effect but also through 
augmentation f host umor-specific immunity. 
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V~ REPERTOIRE ANALYSIS OF TISSUE INFILTRATING CD8+ TCELLS 
RESPONDING TO HINOR HISTOCOHPATIBILITY ANTIGENS 
INVOLVED IN GRAFT-VERSUS-HOST DISEASE 
Friedman, T.}VI.; Castor', D.E.; ffones, S.C.; Komlgold, R. 
KCI/bmmtnology, ffefferson Medical College, Philadelphia, PA. 
Lethal graft versus-host disease (GVHD) can be induced 
between MHC-matched murine strains expressing multiple minor 
histocompatibil ity antigen (miHA) differences. In the B6-> 
BALB.B model, both CD4+ and CDS+ donor can mediate lethal 
GVHD, whereas in the B6->CXBE model (expressing a subset of 
the BALB.B miHA), only the CDS+ T ceils are lethal. CDR3-size 
spectratyping was used to analyze the CD8+ and CD4+ T cell 
responses in both BALB.B and CXBE recipients injected with B6 
CD8+ or CD4+ T cells. Spectratype analysis of the reacting CDS+ 
T ceils indicated overlapping skewing of V]31, 4, 6, 8-10 and 14 
families in both the CXBE and BALB.B recipients and unique 
skewing of the V]3 4 family in the BALB.B recipients. The react- 
ing CD4+ T cells exhibited overlapping expansion of V134, 6-10, 
and 12-14 families, but the B6->BALB.B response also appeared 
to recognize unique BALB.B-specific miHA, indicated by addi- 
tional skewing of V132 and 11. Positively-selected TCR Wo skewed 
CD4+ and CDS+ T cell subsets injected into lethally irradiated 
BALB.B recipients were capable of inducing fatal GVHD. 
BALB.B mice transplanted with non-skewed V]3 CD4+ T cells 
survived with minimal symptoms of GVHD. Here we examine the 
T cell repertoire responses involved in target issue damage. Infil- 
trating B6 host-presensitized CDS+T cells were isolated post- 
transplant from the intestines, livers and spleens of lethally irradi- 
ated CXBE and BALB.B recipients. The results indicated 
overlapping tissue skewing between the B6->BALB.B and B6- 
>CXBE combinations for V]33, 5, 6, 14, and 18 in the spleens, for 
V~5, 9 and 13 in the intestine and V]32 and 18 in the liver. To test 
the possibility that reducing T cell responses within a critical 
GVHD target issue might diminish GVHD lethality we used 
magnetic sorting to remove the intestinal infiltrate skewed V]3 
families from the transplant inoculum. Mice transplanted with 
non-skewed V[3 CDS+ T cells exhibited a two-fold increase in 
median survival time. Taken together these results suggest hat 
differential targeting of T cell responses can be exploited to help 
avoid GVHD. 
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DENDRITIC CELLS CULTURED WITH INTERFERON PLUS GM-CSF CAN 
BE USED TO ELICIT PRI-SPECIFIC CTL FOR ADOPTIVE 
IMMUNOTHERAPY 
Wang, C/; Lu, S/; KJmts, Z.R/: Sukhumalchamlra, P/; Molldrem, 
j.ff.l 1. B3lT/7~ransplant bmmmologL Box 81, M.D. AndersoT~ Cmlcer 
Ceute* , Houstol~, TX; 2.3/1. D. Amterson Crower Center, Houstou, T~. 
We sought a more efficient method to produce potent dendritic 
ceils (DCs) that could be used to elicit PR1-CTL for adoptive 
immunotherapy. Peripheral blood mononuclear cells (PBMC) 
from healthy HLA-A2+ donors were obtained by Ficoll-Hypaque 
separation and monocytes were obtained after two-hour plastic 
adherence. Monocytes were treated for seven days in RPMI medi- 
um plus 10 % human AB serum (HS) with interferon-alpha2b 
(IFN-a) at 1000 units/nil and GM-CSF at 500 units/ml (IF/GM- 
DC). On day seven, the cultures howed a mature phenotype simi- 
lar to DC grown in the same culture media with 1L-4 (1000 
units/ml) and GM-CSF (500 units/ml) (I4/GM-DC): CD83 
(41.9% vs. 39.4%), CDl lc  (90.8% vs.85.23%), CD86, (26.5% vs. 
53.88%) and CD80 (21.9% vs. 35.49%). To compare PRl-specif- 
ic CTL elicited using either DC population, IF/GM-DC and 
IL4/GM-DC were pulsed with PRI at 20 mg/ml, radiated, and 
incubated at a 1:2 ratio with autologous PBMC from HLA-A2+ 
healthy donors. On day 7, 14 and 21 the co-cultures were restimu- 
lated with PR1 pulsed DC, and IL-2 (20 IU/ml) was added the 
following day. PRI -CTL cultures from 6 donors stained with 
PRI/HLA-A2 tetramer showed 0.16% to 5.83% (mean = 1.83%) 
tetramer+ CD8+ lymphocytes from the IF/GM-DC cultures vs. 
0.04% to 7.4% (mean = 1.92%) from the I4/GM-DC cultures 
(p>0.05). IF /GM-DC induced potent PR1-C'I'L proliferation 
with a stimulation index of 2.17 compared with 0.i9 for lympho- 
cytes alone using BrdU incorporation. Mean cytotoxicity results 
from five separate donors showed peptide-specific iysis of 33.8% 
for PRl-coated T2 cells compared with 6.5% for pp65-coated T2, 
at an effector:target ratio of 20:1 by micro-cytotoxicity assay. 
These results how that IFN-a and GM-CSF can be used to elicit 
mature DC cells from PBMC that can be used to elicit PR1-CTL 
after only 21 days of culture. 
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PHASE III TRIAL WITH INFLIXIHAB/HETHYLPREDNISOLONE (HP) VS 
MP FOR THE TREATMENT OF ACUTE GVHD: PRELIMINARY FINDINGS 
Couriel, D.R.; Hicks, K.; Gimlt, S.; Ippoliti, C.; Khouvi, I.; de Lima, 
M.; Homon, E.; Coheir, A.; HosiTzg, C.; Donato, M.; A11derlini, P.; 
Molldrem, tiff.; Gajewski, J.; Champ/in, R. Blood mJd Mar'row Tram- 
pkmtation, UT MD Anderson Cancer Center, Hollstolz, T~\: 
Preclinical and human studies of acute GVHD (aGVHD) suggest 
that tumor necrosis factor-alpha (TNF a) may play an important 
pathogenic role in aGVHD. We have previously reported a high 
response rate in the treatment of steroid-refractory aGVHD with 
infliximab, a chimeric human-monse anti- TNF-a monoclonal anti- 
body. In this study, we vahiate the efficacy and toxicity of inflLximab 
in the upfront reatment of aGVHD. Methods: Single institution, 
open-label, randomized, controlled trial that compares the combina- 
tion of infliximab with MP versus MP in the upfi'ont reatment of 
grade 2 or higher aGVHD. After stratification according to donor 
type and the presence or absence of GI involvement, patients were 
randomized to receive MP (2 mg/kg/day with standardized taper) 
plus infli~mab (10 mg/kg weekly x 4 weeks) or MP alone. Results: 
The trial has currently enrolled 52 patients with an accrual goal of 
100 patients. Of 39 patients evahiable for response, the overall 
response rate of GVHD was 63% (12/19) in the MP + inflLximab arm 
and 50% (10/20) in the MP arm. CR was observed in 11/12 treated 
with MP+ inflixiInab, and all 10 responders in those receiving MP 
alone (p=NS). In the infliximab group responses were observed in 
aGVHD of the skin (n= 10) and the GI tract (n- 5). Fourteen (60%) 
patients in the MP+ inflLximab arm developed one or more bacterial, 
viral or fimgal infections compared to 12 (60%) in the NIP arm (p= 
NS). Median survival was 208 and 168 days for the MP+ infliximab 
and MP groups respectively, and no statistical differences in mortality 
have been observed between the two arms. Number and causes of 
deaths are shown in the Table. Conclusions: So tar, both the MP+ 
inflLximab and MP arms show a similar profile of efficacy, toxicity and 
relapse rate. Both arms have a comparable and relatively high preva- 
lence of infection, highlighting the need for aggressive monitoring 
and prophylaxis nthis population. This study continues accrual. 
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ENGRAFTMENT, GVHD, IMMUNE RECONSTITUTION AND SURVIVAL 
FOLLOWING CDS+ T CELL DEPLETED ALLOGENEIC PERIPHERAL 
BLOOD STEM CELL TRANSPLANTATION (PBSCT) 
Soiff'e'r, R.J.; Alyea, E.P.; Hochbevg, E.; Ho, l'~; Lee, S.; Parileh, B.; 
Fisher, D.; Amil~, ft. Dana Favber CmTce1" hlstimte, Bosto'n, }VIA. 
Partial depletion of CD8+ T cells from donor lymphocyte infu- 
sions reduces the incidence of GVHD without comprmuising 
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anti-tumor activity. We hypothesized that partial depletion of 
CD8 cells might have a similar effect as primary GVHD prophy- 
laxis after alIo-PBSCT. We report a series of 25 patients (pts) 
(median age 47 yrs, 17M/8F) with hematologic malignancies (13 
AML, 4 NHL, 3 ALL, 3 MDS, 1 CML, 1 CLL) who underwent 
PBSCT utilizing HLA matched sibling donors. Pts received 
cyclophophamide and fractionated TBI (1400 cGy). Stem ceils 
were depleted of CDS+CD3+ T ceils with antibody coated high 
density microparticles (CD8-HDM, Biotransplant, Charlestown, 
MA). 20/25 were transplanted for advanced isease. GVHD pro- 
phylaxis consisted of tacrolimus (0.02mg/kg 1VCI daily) alone 
without methotrexate. Donors were mobilized with filgastrim (10 
mcg/kg/d x 5d) prior to stem cell collection. The median number 
of CD34+ cells infused was 5.9 x 10e6/kg (range, 2.1-22.1 x 
10e6/kg), 80% recovery. The number of CD3+CD4+ cells/kg 
infused was 5.3 x 10e7/kg (range, 1.8-9.0 x 10e7/kg) while the 
number of CD3+CD8+ cells was 1.9 x 10e5/kg (range, 0.1-5.2 x 
10eS/kg), >99% depletion. All patients engrafted. An absolute 
neutrophil count of 500/1 was achieved on Day +10 (range, 9-12). 
Sustained platelet counts of 20, 00W1 were attained on Day +14 
(range, 8-42). Chilnerism studies revealed 98-100% donor cells in 
17/17 pts tested. At 3 mouths, CD4+ T cells in peripheral blood 
outnumber CD8 + T cells. The CD4/CD8 ratio was 2.5 (range 
0.8-11.9). Most of the CD4+ cells were CD45RO+ while the 
majority of CD8 cells were CD45RA+. Grades 2-4 acute GVIID 
occurred in 11/25 patients (44%). Two patients have limited 
chronic GVItD. With a median follow-up of 270 days (range, 
123-376), 20/25 patients (80%) are alive, NED. There have been 
4 transplant related deaths (1 pneumonitis, 1 hepatic veno-occlu- 
sive disease, I Listeria meningitis, 1 GVHD) and 1 relapse. Our 
results suggest hat depletion of CDS+ T cells from mobilized 
blood with the CD8-HDM device does not hinder hematopoietic 
recove W after allo-PBSCT. The incidence of acute GVttD was 
less than that reported in pts receiving a calcineurin inhibitor 
aIone as the sole form of GVHD prophylaxis. Further follow-up is 
needed to determine the effects of CD8 depletion on rates of 
chronic GVHD and relapse. 
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INFLIXIMAB FOR GVHD THERAPY IN CHILDREN 
Sleight, Bd; Cl:mT, K.:; Serrmm, A); Gil'ma,, A.; 1. Pediatries, Yale 
U, iversity, New Haven, CT; 2. 3lID Ancterso17 Ca,cer Ce~tte'r, Holts- 
ton, TX; 3. C/:ildreTz's Mercy Hospital, K:msas City, MO. 
Infliximab inhibits TNF% a major mediator of GVHD patho- 
genesis. In this retrospective r view, we analyzed the use, response 
and to,city of infliximab given for 33 episodes of GVHD in 24 
children. Ages ranged from 4 too-18 yrs (median 5y), with 18 sub- 
jects <10 yo. Diagnoses included ALL (I 1), AML (4), SAA (4), and 
1 each with ALD, NHL, Fanconi's anemia, Hurler and Omenn's 
syndrome. Eighteen patients had 25 episodes of aGVHD. Sixteen 
had steroid refractory aGVHD, in addition, 6/18 subjects were 
refractory to ATG (3) +/or daclizumab (4). At initiation of inflix- 
imab, episodes of aGVHD were grade I-Ii (1I) and grade III-IV 
(14). Infli~mab (10 mg/kg) was administered I-3x per week. Dos- 
ing frequency was increased for 2 patients with protein-losing 
enteropathy. In aGVHD patients, 110 total doses were given 
(range 1-58; median 3 doses per flare). Many patients with signifi- 
cant GVt ID or symptoms received infliximab combined with 
other immunosuppressants i cluding: initiation of or an increased 
dose of MP (3), daclizumab (4), ATG (3), plaquenil (2), MMF (2), 
thalidomide (1), fludarabine (1) an d photopheresis (1). Of evalu- 
able patients, improvement was se~n in 15/16 (94%) episodes of 
skin GVHD [CR I3/16 (81%)] and 11/14 (79%) episodes of G1 
GVHD [CR 11/14 (79%)]. One of 3 cases of liver GVHD 
responded. Responses were assessed as the best response within 56 
days after starting infliximab. Only 2 of 18 subjects with aGVHD 
are  surviving. Eight patients had 9 episodes of extensive cGVHD. 
Several patients were treated for an acute flare of cGVHD. The 
majority of patients were receiving steroids, TAC/CsA and 
plaquenil. One patient had recently received 2CDA and 2 started 
daclizumab shortly before infliximab. 426 doses of infliximab 
(10mg/kg) were given (range 5-I62; median 16 doses). Two 
patients received 157 and 162 doses, resp. Five of 8 patients 
improved. Only 3 of 8 subjects with cGVHD are surviving with 
many deaths attributed to cGVHD. Prolonged high-dose inflix- 
imab therapy was well tolerated. No infusion related adverse 
events occurred. Many infectious complications (bacterial, viral, 
fimgal) developed as a result of lnuhi-modality imnmnosuppres- 
sion in these high-risk patients. No cases of mycobacterial infec- 
tions were seen. No increased rate nor predominant type of infec 
tion was noted. Infliximab has activity in children with acute and 
chronic GVHD and warrants prospective analysis. 
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MODULATION OF HOST DENDRITIC CELLS BY EXTRACORPOREAL 
PHOTOPHORESIS IN AN ALLOGENEIC BONE MARROW TRANSPLANT 
CONDITIONING REGIMEN 
C'l:a~, G.; Miller, K.; Foss, F. Tl~'ts-New E,g:land 3,h, dical Ce,te/', 
Bosto,, k/b1. 
We demonstrated that Extracorporeal Photophorcsis (ECP) 
ameliorates chronic graft-versus-host disease (cGVHD) by 
decreasing circulating dendritic cell (DC) number and func- 
tion. To explore whether ECP could prevent GVHD through 
similar mechanisms, we transplanted 56 high-risk patients 
with a reduced intensity conditioning regimen of ECP for 2 
days, pentostatin (8rag/m2 by continuous infusion over 48 hr), 
and 600 cGy of TBI. Seven patients (2F, 5M), median age 59 
(range 32 to 70), with MI)S (n=4), AML (n=l), myelofibrosis 
(n=I), or NHL (n=l), were studied to determine the effects of 
ECP on host DC subsets prior to stem cell infusion and DC 
reconstitution. Flow cytometry used CD1 lc to identify mono 
cytoid DC1 cells and CD123 to identify plasmacytoid DC2 
cells. After the two days of ECP, DCls decreased a median of 
3% (range -39 to +35%), while DC2s decreased a median of 
47% (range -I00 to +51%). Five patients developed full donor 
mononuclear ceil and DC chimerism by day 100 with no 
grade 2-4 acute GVHD.  in this group, DC ls  and DC2s 
decreased in 2 and 4 patients respectively. Of the 2 patients 
who failed to engraft, both had decreases in DC1 and one had 
a decrease in DC2 cells. While our sample size is small, the 
data suggest hat ECP induces similar changes in DC subsets 
in these patients as in our patients with cGVHD. Since the 
overall incidence of grade 2-4 aGVHD in 56 patients was 
10%, these preliminary data suggest hat immunomodulation 
of host DCs by ECP prior to allogeneic stem cell infusion 
may play a role in reducing alloreactivity and thereby attenu- 
ate the incidence and severity of aGVHD. Further studies will 
be needed to determine whether these immunomodulatory 
effects of ECP prior to allogeneic stem cell infusion are corre- 
lated with incidence and severity of GVHD in other condi- 
tioning regimens. 
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DONOR CD8 T-CELL SUPPORT OF HEMATOPOIETIC PROGENITOR 
ACTIVITY DURING SYNGENEIC BMT 
Ha~zash, A.M.; Levy, R.B. Micribiology & Immu,ology, University of 
Miami School of MedMne, Miami, FL. 
Efforts to reduce graft vs. host disease (GVHD) during bone 
marrow transplantation (BMT) by removing donor T-cells from 
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